302 related articles for article (PubMed ID: 34149732)
1. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
Cui Y; Cai J; Wang W; Wang S
Front Immunol; 2021; 12():690207. PubMed ID: 34149732
[TBL] [Abstract][Full Text] [Related]
2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
4. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
5. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
[TBL] [Abstract][Full Text] [Related]
6. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Koutsounas I; Giaginis C; Patsouris E; Theocharis S
World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
[TBL] [Abstract][Full Text] [Related]
7. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
9. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
Adeshakin AO; Adeshakin FO; Yan D; Wan X
Front Immunol; 2022; 13():781660. PubMed ID: 35140716
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: insights into mechanisms of lethality.
Rosato RR; Grant S
Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
[TBL] [Abstract][Full Text] [Related]
11. Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors.
Huang M; Geng M
Sci China Life Sci; 2017 Jan; 60(1):94-97. PubMed ID: 27888384
[No Abstract] [Full Text] [Related]
12. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
13. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
[TBL] [Abstract][Full Text] [Related]
17. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: anticancer compounds.
Smith KT; Workman JL
Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
20. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
